Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationClear · solid tumours
Clear Solid
Watching for trace ctDNA after curative-intent treatment: the earliest molecular sign that a solid cancer may be returning.
01Clear Solid
MRD surveillance for solid tumours
After curative-intent treatment for a solid tumour, whether surgery, radiotherapy or systemic therapy, Clear Solid watches for trace ctDNA: the earliest molecular sign that a cancer may be returning.
02
Tumour-informed monitoring
Tuned to your specific cancer.
The most sensitive MRD approach is tumour-informed, built around the specific mutations found in your own tumour. Where a baseline exists, for example from a Signature test, Clear Solid tracks exactly the right signals. That improves the odds of catching a true return while limiting false alarms.
Diagram placeholder
Molecular signal rising before the scan changes
03
What you receive
Results in context
Scheduled surveillance read against your own baseline.
Clinician review
KPCIRC reviews any change, rather than an automated alert.
A plan if a signal appears
Including prompt imaging and next-step options.
Being clear about our limits
What we do and do not do
What we DO
- Watch for returning disease after curative-intent treatment
- Often flag recurrence earlier than routine imaging
- Trigger a KPCIRC clinician review on a changing signal
- Personalise how closely follow-up is done
What we DON’T do
- Diagnose recurrence on its own, findings are confirmed
- Detect every recurrence, since some tumours shed little ctDNA
- Replace your scheduled scans and specialist follow-up
- Guarantee that acting earlier will change the outcome
Plain-language glossary (5 terms)
| Term | What it means |
|---|---|
| MRD | Molecular residual disease, microscopic disease left after treatment. |
| ctDNA | Circulating tumour DNA, tumour fragments a blood test can read. |
| Tumour-informed | An MRD test built from your own tumour’s mutations, for higher sensitivity. |
| Recurrence | The cancer returning after a period of remission. |
| Lead time | How far ahead of a scan a blood test can flag returning disease. |
Important information and regulatory status
Clear Solid is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.
- A result is not a diagnosis and does not by itself decide treatment.
- A “not detected” result does not rule out cancer or a genetic change.
- Not all cancers release enough DNA into blood to be detected.
- We cannot guarantee that a medicine will be available, approved, covered or effective.
- Collection kits are for qualified phlebotomists. They are not for self-testing.
- Confirmatory testing may be required.
Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner (CAP-accredited, ISO 15189) following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
Take the next step
Three ways forward. Pick the one that fits today.
Begin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal